Analysis of the efficacy and survival of third-line treatment in advanced non-small cell lung cancer

Chinese Journal of Lung Cancer

Volumn 15, Issue 6, 2012, Pages 369-374

  Shao, Lan ^a   Song, Zhengbo ^b   Hu, Lin ^a   Xie, Fajun ^b   Lou, Guangyuan ^b   Hong, Wei ^b   Gu, Cuiping ^b   Hong, Dan ^b   Lin, Baochai ^a   Zhang, Yiping ^b  

^a ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^b ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

Chemotherapy; Lung neoplasms; Prognosis; Targeted therapy; Third line treatment

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB;

CANCER CHEMOTHERAPY; CANCER DOUBLET CHEMOTHERAPY; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; REVIEW; SURVIVAL TIME;

EID: 84995304377     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2012.06.08     Document Type: Review

References (16)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin, 2009, 59(4): 225-249.
2. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol, 2006, 24(28): 4539-4544.
3. Petrelli NJ, Winer EP, Brahmer J, et al. Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology. J Clin Oncol, 2009, 27(35): 6052-6069.
4. Syrigos KN, Saif MW, Karapanagiotou EM, et al. The need for thirdline treatment in non-small cell lung cancer: an overview of new options. Anticancer Res, 2011, 31(2): 649-659.
5. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 2000, 18(10): 2095-2103.
6. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 2005, 366(9496): 1527-1537.
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 2005, 353(2): 123-132.
8. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 2004, 22(9): 1589-1597.
9. Sun JM, Lee KW, Kim JH, et al. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer. Jpn J Clin Oncol, 2009, 39(1): 27-32.
10. Girard N, Jacoulet P, Gainet M, et al. Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice. J Thorac Oncol, 2009, 4(12): 1544-1549.
11. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA, 2003, 290(16): 2149-2158.
12. Scartozzi M, Mazzanti P, Giampieri R, et al. Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable? Lung Cancer, 2010, 68(3): 433-437.
13. Di Maio M, Chiodini P, Georgoulias V, et al. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as secondline treatment of advanced non-small-cell lung cancer. J Clin Oncol, 2009, 27(11): 1836-1843.
14. Chen YM, Perng RP, Shih JF, et al. Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy. J Thorac Oncol, 2006, 1(6): 545-550.
15. Kim HS, Lee GW, Kim JH, et al. A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with nonsmall cell lung cancer. Lung Cancer, 2010, 70(1): 71-76.
16. Smit EF, Burgers SA, Biesma B, et al. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol, 2009, 27(12): 2038-2045.